Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Completed · Phase 3 · Has a placebo group

Conditions studied: Hereditary Periodic Fevers

In brief

This study is to determine whether canakinumab is able to induce and maintain a clinically meaningful reduction of disease activity in participants with Hereditary Periodic Fevers (HPF) compared to placebo.

Key facts

Study ID
NCT02059291
Run by
Novartis Pharmaceuticals
People needed
203
Starts
2014-06-27
Expected to finish
2017-07-04
Last updated by the study team
2018-05-17

Who can join

Age: 0 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.